Edge Rewrite
restyle Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

SCTV01C

From Wikipedia, the free encyclopedia

SCTV01C
Vaccine description
TargetSARS-CoV-2
Vaccine typeProtein subunit
Clinical data
Routes of
administration		Intramuscular
Identifiers
CAS Number

SCTV01C is a COVID-19 vaccine candidate developed by Sinocelltech.[2][3][4]

References

[edit]
  1. ↑ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
  2. ↑ "The Safety and Efficacy of SCTV01C in Population Aged ≥18 Years Previously Vaccinated With Inactivated COVID-19 Vaccine.Healthy Population Aged ≥18 Years Previously Vaccinated With Adenovirus Vectored or mRNA COVID-19 Vaccine". United States National Library of Medicine. 14 September 2021. NCT05043311. Retrieved 14 September 2021.
  3. ↑ "The Safety and Efficacy of SCTV01C in Population Aged ≥18 Years Previously Vaccinated With Inactivated COVID-19 Vaccine.Healthy Population Aged ≥18 Years Previously Vaccinated With Inactivated COVID-19 Vaccine". United States National Library of Medicine. 14 September 2021. NCT05043285. Retrieved 14 September 2021.
  4. ↑ "Safety, Tolerability and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Unvaccinated". United States National Library of Medicine. 8 December 2021. NCT05148091. Retrieved 8 December 2021.


Retrieved from "https://en.wikipedia.org/w/index.php?title=SCTV01C&oldid=1247453077"